Advanced search
Publication Cover
Modern Rheumatology Volume 28, 2018 - Issue 1
Journal homepage
3,587
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study

Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; View further author information
,
Taeko IshiiMedicines Development Unit Japan, Eli Lilly Japan K.K, Kobe, Japan; Correspondence[email protected]
View further author information
,
Zhihong CaiMedicines Development Unit Japan, Eli Lilly Japan K.K, Kobe, Japan; View further author information
,
Douglas SchlichtingEli Lilly and Company, Indianapolis, IN, USAView further author information
,
Terence RooneyEli Lilly and Company, Indianapolis, IN, USAView further author information
&
William MaciasEli Lilly and Company, Indianapolis, IN, USAView further author information
Pages 20-29 | Received 01 Dec 2016, Accepted 14 Mar 2017, Published online: 25 Apr 2017

Related Research Data

Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.
Source: Hindawi Limited
Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
Source: Informa UK Limited
JAK Inhibitors for Atopic Dermatitis: An Update
Source: Springer Science and Business Media LLC
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Source: BMJ
Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials
Source: Informa UK Limited
JAK/STAT inhibitors for the treatment of atopic dermatitis
Source: Informa UK Limited
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
Source: Springer Science and Business Media LLC
Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Source: BMC

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.